GlaxoSmithKline’s (GSK) Europe market reported ~1.0% growth in revenues to ~1.0 billion pounds in 4Q17.
GSK’s Pharmaceuticals segment reported revenues of ~4.5 billion pounds during 4Q17, an ~1.0% decrease in revenues compared to 4Q16.
GlaxoSmithKline (GSK) reported revenues of 7.64 billion pounds in 4Q17, reflecting 1.0% growth compared to 7.59 billion pounds in 4Q16.
Despite its robust efficacy profile, Aimovig has shown a safety and tolerability profile similar to that of a placebo.
Aimovig, which is Novartis’s (NVS) investigational migraine prophylaxis therapy, is under review by the FDA and the European Medicines Agency.
Lutathera and SEG101 are expected to significantly strengthen Novartis’s position in the oncology segment.
Jakavi reported sales of $228.0 million in 4Q17, which is a year-over-year rise of 33.0% on a constant currency basis.
On November 8, 2017, Novartis announced the positive preliminary results from its Phase 3 trial, MONALEESA-7.
Kymriah is the first FDA-approved chimeric antigen receptor T cell (or CAR-T) therapy.
The National Cancer Institute estimates that the incidence of ALL in patients aged 20 or younger is ~3,100 in the US.
On November 6, 2017, Novartis (NVS) announced positive data from the MEASURE 1 trial, which highlighted the potential of Cosentyx in preventing the progression of disease in the majority of the…
Only 525,000 patients (or 55% of the diagnosed psoriatic arthritis patients) were eligible for treatment with biologics.
In 4Q17, Novartis’s (NVS) Cosentyx reported global sales of $615.0 million, which is a year-over-year increase of 53.0%.
Of the 12 analysts covering AMAG Pharmaceuticals, three have given the stock a “buy” or higher rating, and nine have given it a “hold.”
In 4Q17, Boston Scientific’s (BSX) Cardiovascular business segment reported sales of $913 million.
In 4Q17, Boston Scientific’s (BSX) Cardiovascular business registered strong YoY (year-over-year) sales growth of ~8.7% on a reported basis.
In 4Q17, Boston Scientific’s (BSX) MedSurg segment witnessed double-digit YoY (year-over-year) growth of ~14.2%, on a reported basis.
Boston Scientific’s 4Q17 revenue came in at $2.41 billion, exceeding Wall Street’s estimate of ~$2.38 billion.
BSX operates in three business segments: MedSurg, Rhythm Management, and Cardiovascular.
On February 1, 2018, Boston Scientific (BSX) announced its 4Q17 and 2017 earnings results.